Galvani E, Mundra P, Valpione S, et al. Low tumour heterogeneity but not mutational burden correlates with response to anti-PD-1 treatment in a mouse model of melanoma. SMR 2017, abstract SMR4-04.
Neoadjuvant pertuzumab plus trastuzumab met of zonder chemotherapie: 5-jaarsoverlevingsdata
jun 2022 | Borstkanker